Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

132 questions · 147 findings · 29 reviews · Neonatal

No studies found 41 · 27.9%GRADE not reported 4 · 2.7%Very low 29 · 19.7%Low 43 · 29.3%Moderate 19 · 12.9%High 11 · 7.5%

Systemic administration of beta‐blockers vs placebo or no treatment

Rescue treatment with anti‐VEGF agents · Prevention of retinopathy of prematurity in preterm infants

Systemic administration of beta‐blockers may leads to lower rescue treatment with anti‐VEGF agents compared with placebo or no treatment (low certainty).

1 finding from 1 review

Systemic administration of beta‐blockers vs placebo or no treatment

Treatment with laser photocoagulation or cryotherapy · Prevention of retinopathy of prematurity in preterm infants

Systemic administration of beta‐blockers may leads to lower treatment with laser photocoagulation or cryotherapy compared with placebo or no treatment (low certainty).

1 finding from 1 review

Systemic administration of beta‐blockers vs placebo or no treatment

Progression to stage 2 with plus disease · Prevention of retinopathy of prematurity in preterm infants

Systemic administration of beta‐blockers showed no clear difference in progression to stage 2 with plus disease compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Systemic administration of beta‐blockers vs placebo or no treatment

Progression to stage 3 ROP · Prevention of retinopathy of prematurity in preterm infants

Systemic administration of beta‐blockers probably leads to lower progression to stage 3 ROP compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Systemic administration of beta‐blockers vs placebo or no treatment

Progression to stage 4 or 5 ROP · Prevention of retinopathy of prematurity in preterm infants

Systemic administration of beta‐blockers showed no clear difference in progression to stage 4 or 5 ROP compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Systemic administration of beta‐blockers vs placebo or no treatment

Arterial hypotension and/or bradycardia requiring treatment · Prevention of retinopathy of prematurity in preterm infants

Systemic administration of beta‐blockers may leads to higher arterial hypotension and/or bradycardia requiring treatment compared with placebo or no treatment (low certainty).

1 finding from 1 review

Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or

Failed apnea reduction · treatment of apnea

Doxapram showed no clear difference in 1a. Failed apnea reduction after 2–7 days – doxapram compared to no… compared with no treatment, placebo, methylxanthine (including theophylline,… (low certainty).

3 findings from 1 review

Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or

4b. Death at any time during initial hospitalization – doxapram compared to alternative treatment for the treatment of apnea · treatment of apnea

The review found no eligible studies for this question.

2 findings from 1 review

Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or

5a. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to no treatment for the treatment of apnea · treatment of apnea

The review found no eligible studies for this question.

1 finding from 1 review

Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or

5b. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to alternative treatment for the treatment of apnea · treatment of apnea

The review found no eligible studies for this question.

1 finding from 1 review

Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or

5c. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the treatment of apnea · treatment of apnea

The review found no eligible studies for this question.

1 finding from 1 review

Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or

side‐effects ‐ side‐effects causing abandon · treatment of apnea
3 findings from 1 review

Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or

1a.'Clinical apnea' after initiation of treatment – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation

The review found no eligible studies for this question.

2 findings from 1 review

Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or

1c.'Clinical apnea' after initiation of treatment – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the prevention of reintubation · prevention of reintubation

Doxapram may leads to lower 1c.'Clinical apnea' after initiation of treatment – doxapram as an… compared with no treatment, placebo, methylxanthine (including theophylline,… (low certainty).

1 finding from 1 review

Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or

2b. Failed apnea reduction after 2–7 days – doxapram compared to alternative treatment for the prevention of reintubation · prevention of reintubation

It is very uncertain whether doxapram changes 2b. Failed apnea reduction after 2–7 days – doxapram compared to… compared with no treatment, placebo, methylxanthine (including theophylline,… (very low certainty).

1 finding from 1 review

Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or

2c. Failed apnea reduction after 2–7 days – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the prevention of reintubation · prevention of reintubation

Doxapram showed no clear difference in 2c. Failed apnea reduction after 2–7 days – doxapram as an adjunct… compared with no treatment, placebo, methylxanthine (including theophylline,… (low certainty).

1 finding from 1 review

Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or

3a. Chronic lung disease at 36 weeks' postmenstrual age – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation

The review found no eligible studies for this question.

1 finding from 1 review